Families choosing to bank their stem cells – usually in the form of cord blood and/or dental pulp stem cells, typically view their decision as “biological insurance.” A Phase II clinical trial is investigating the safety and efficacy of autologous [the patient’s own] cord blood stem cells to treat children with behavioral and social difficulties associated with Autism Spectrum Disorder (ASD). In a clear demonstration of the value of banking your own stem cells, only families that chose to bank their children’s cord blood were qualified to participate in the study.
The study, conducted at Duke University, was a double-blind investigation into the use of autologous stem cells to augment language and behavior of autistic children. Over the course of 6 months, autistic children ages 2-7 received intravenous stem cell infusions with the aim of helping malfunctioning neurons make repairs that would facilitate speech and behavior. With some patients showing improvement, future clinical trials will seek to improve efficacy through the exploration of alternate dosages or methods of delivery.
None of the participating families could have predicted a future diagnosis of ASD. Eligibility to participate in this clinical trial supports the wisdom of banking your own stem cells to facilitate access to emerging stem cell based treatments. We believe the best stem cells to use will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn how to bank your own valuable stem cells to insure your future health, visit www.StemSave.com or call 877-783-6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.